MPM invests in biotechnology, specialty pharma, medical technology, and related companies that provide innovative medical products and requisite services to the healthcare industry, irrespective of geography, stage of development and therapeutic area. We seek to maximize value creation by focusing on inflection points in the development of companies, such as the achievement of clinical proof-of-concept data, the achievement of early commercial success, and by reinvigorating commercial platforms with potentially high growth assets. We believe that by investing at or near a company's value inflection points, and by lending our internal expertise to management teams, we can often significantly accelerate the development of a company. Also with our commitment to build companies, we can help focus a company's investments on the projects and opportunities with the highest reward/risk ratio.
For more than 30 years InterWest has partnered with exceptional entrepreneurs to build winning technology and life sciences companies. With more than 200 years of combined operating and investing experience, our team has raised $2.8B, completed more than 70 IPOs, and participated in nearly 60 upside acquisitions. As we invest InterWest X, a $650M fund, we continue to believe that providing capital is just the beginning of a long-term collaboration with entrepreneurs to turn their vision into a thriving company.
Polaris Venture Partners is a partnership of experienced investors, operating executives and entrepreneurs. The firm's mission is to identify, invest in and partner with seed, early stage, and middle market businesses with exceptional promise and help them grow into market-leading companies. In addition, we are committed to providing growth equity and shareholder liquidity to established companies in the technology, healthcare, manufacturing, media, communications, and business services sectors. As a national venture capital firm with offices in the high-tech centers of Boston and Seattle, we are able to invest in businesses throughout the United States and around the world. We invest in businesses across a number of markets including digital media, technology, consumer, enerTech and life sciences. The firm has over $3 billion under management, more than 20 investment professionals, and current investments in more than 115 companies.
Founded in 1991, Frazier Healthcare Ventures is a leading provider of venture and growth equity capital to emerging biopharma, medical device and healthcare service companies. With over $1.8 billion under management, Frazier Healthcare has invested in over 100 companies across the entire development spectrum. From seed stage venture investments to leveraged recapitalizations of cash generating companies, Frazier Healthcare Ventures has established itself among entrepreneurs and seasoned executives as a preferred partner to create and grow successful healthcare companies.
Built on a foundation that leverages 20 years of North American venture capital experience, the Lumira Capital team has substantial experience helping to build transformational health and life science companies.
Our goal is to make investments in market leading companies and work in partnership with those companies to develop and implement strategies to build significant businesses that in turn allow us to generate profitable exits that maximize returns within a reasonable time frame.
As partners in our businesses we are committed to the success of our portfolio companies. We roll up our sleeves and work side by side with our entrepreneurs, their management teams and our syndication partners – leveraging our internal resources, knowledge networks, deep industry expertise and relationships, as well as our operational and leadership experience to help the businesses achieve their full potential.
Johnson & Johnson Development Corporation is the venture capital subsidiary of Johnson & Johnson. We are comprised of experts and leaders in the health care and technology venture communities who identify early market indicators, health care trends, and strategic investment opportunities. Unlike traditional venture capital firms, we determine the success of an investment's performance not only in financial returns, but also in the viability of providing strategic growth options for Johnson & Johnson.
We play an integral role in the identification of new business opportunities outside of Johnson & Johnson's traditional portfolio and market presence. We identify white space opportunities and develop new businesses in emergent health care sectors while also creating support venture investments in alignment with the strategic objectives of Johnson & Johnson operating companies.
West River Capital is a venture capital firm specializing in early stage investments. It seeks to invest in biotechnology, software, and telecommunications sector. West River Capital was founded in 2002 and is based in Kirkland, Washington.
Formed in 2005 by the merger of Diamond Capital and UFJ Capital, Mitsubishi UFJ Capital has financed more than 1,000 companies worldwide. Of these companies, more than 290 have gone public.
We have a multi-sector investment focus with increasing focus on healthcare, biotech, IT, electronics and high technology (currently accounting for 60% of new investments). Companies offering products, solutions and services to the Japanese market as well as solutions and services of interest to Japanese companies are also of special focus to Mitsubishi UFJ Capital.